valproic acid has been researched along with Myelodysplastic Syndromes in 41 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in high-risk myelodysplastic syndromes (MDS) cases with unfavorable prognosis." | 9.15 | Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. ( Chiarini, F; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Martelli, AM; Martinelli, G; Mongiorgi, S; Paolini, S; Ramazzotti, G, 2011) |
| "We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients." | 9.12 | Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. ( Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H, 2006) |
| " In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML." | 6.73 | Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. ( Hallman, H; Honkanen, T; Juvonen, E; Kauppila, M; Koistinen, P; Kutila, A; Mikkola, M; Nyländen, P; Poikonen, E; Rauhala, A; Savolainen, ER; Siitonen, T; Sinisalo, M; Suominen, M; Terävä, V; Timonen, T, 2007) |
| "Valproic acid (VPA) has been shown to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in the differentiation induction of acute myelogenous leukemia (AML) blasts in vitro." | 6.71 | Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. ( Aivado, M; Bernhardt, A; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Kuendgen, A; Strupp, C, 2004) |
| "Valproic acid (VPA) is an effective first-line anticonvulsant that is associated with several side effects including bone marrow suppression and subsequent cytopenia." | 5.72 | Valproic Acid Induced Thrombocytopenia and Dysmegakaryopoiesis in a Pediatric Patient. ( Akgun, Y; Baykara, Y; Langlie, J; Poveda, J; Van Truong, L, 2022) |
| "The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in high-risk myelodysplastic syndromes (MDS) cases with unfavorable prognosis." | 5.15 | Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. ( Chiarini, F; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Martelli, AM; Martinelli, G; Mongiorgi, S; Paolini, S; Ramazzotti, G, 2011) |
| "We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients." | 5.12 | Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. ( Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H, 2006) |
| "Two demethylating agents are approved in myelodysplastic syndromes (MDS): 5-azacitidine and 5-aza-2'-deoxycitidine (decitabine)." | 4.84 | Demethylating agents in myeloid malignancies. ( Garcia-Manero, G, 2008) |
| " We conclude that VPA is a safe and effective treatment option for MDS and AML patients, particularly when used in conjunction with all-trans retinoic acid, DNA-hypomethylating drugs, and hydralazine." | 3.01 | Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review. ( Mahdiani, S; Mohammadpour, AH; Omidkhoda, N; Rahimi, H; Samadi, S, 2023) |
| "The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day." | 2.76 | Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. ( Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S, 2011) |
| "To evaluate the efficacy and adverse effect of valproic acid (VPA) in combination with low dose chemotherapy on intermediate and high-risk myelodysplastic syndrome." | 2.76 | [The efficacy and safety of valproic acid in combination with low dose chemotherapy on intermediate and high-risk myelodysplastic syndrome]. ( Ge, GM; Han, XL; He, LS; Huang, Y; Wu, S; Yan, YP; Zhang, QY, 2011) |
| " In conclusion, the combination studied is safe and has significant clinical activity." | 2.73 | Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. ( Cortes, J; Estey, EH; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Issa, JP; Kantarjian, HM; Ouzounian, S; Pierce, S; Quezada, A; Ravandi, F; Soriano, AO; Wierda, WG; Yang, H, 2007) |
| " In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML." | 2.73 | Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. ( Hallman, H; Honkanen, T; Juvonen, E; Kauppila, M; Koistinen, P; Kutila, A; Mikkola, M; Nyländen, P; Poikonen, E; Rauhala, A; Savolainen, ER; Siitonen, T; Sinisalo, M; Suominen, M; Terävä, V; Timonen, T, 2007) |
| "Valproic acid (VPA) has been shown to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in the differentiation induction of acute myelogenous leukemia (AML) blasts in vitro." | 2.71 | Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. ( Aivado, M; Bernhardt, A; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Kuendgen, A; Strupp, C, 2004) |
| " For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs." | 2.71 | Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. ( Fox, F; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Knipp, S; Kuendgen, A; Steidl, C; Strupp, C, 2005) |
| "Valproic acid (VPA) is an HDACi and has been known as anti-epileptic agent for many years." | 2.44 | Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. ( Bellos, F; Mahlknecht, U, 2008) |
| " Recent clinical trials investigate new dosing schedules, routes of administration, and combination regimens." | 2.44 | Current status of epigenetic treatment in myelodysplastic syndromes. ( Kuendgen, A; Lübbert, M, 2008) |
| "Valproic acid (VPA) is an effective first-line anticonvulsant that is associated with several side effects including bone marrow suppression and subsequent cytopenia." | 1.72 | Valproic Acid Induced Thrombocytopenia and Dysmegakaryopoiesis in a Pediatric Patient. ( Akgun, Y; Baykara, Y; Langlie, J; Poveda, J; Van Truong, L, 2022) |
| "Hydralazine was dosed according to the acetylation genotype of patients (slow acetylators 83 mg daily; fast acetylators 182 mg daily), and valproate was dosed at 30 mg/kg/day." | 1.46 | Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). ( Burgos, S; Candelaria, M; Dueñas-Gonzalez, A; Espinoza, R; Ponce, M, 2017) |
| "Co-treatment with VPA and bortezomib on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cell lines resulted in marked inhibition of proliferation and induction of apoptosis, including a striking increase in mitochondrial injury, caspase cascade activation, and altered expression of Bcl-2 family proteins." | 1.37 | Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. ( Chen, L; Li, JM; Shen, ZX; Wang, AH; Wei, L; Wu, WL; Zhao, SQ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.32) | 18.2507 |
| 2000's | 20 (48.78) | 29.6817 |
| 2010's | 15 (36.59) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, AH | 1 |
| Seymour, JF | 1 |
| Akgun, Y | 1 |
| Baykara, Y | 1 |
| Langlie, J | 1 |
| Van Truong, L | 1 |
| Poveda, J | 1 |
| Omidkhoda, N | 1 |
| Mahdiani, S | 1 |
| Samadi, S | 1 |
| Rahimi, H | 1 |
| Mohammadpour, AH | 1 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 3 |
| Sekeres, MA | 2 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 1 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 1 |
| Rose, C | 1 |
| Vey, N | 1 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 4 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 2 |
| Candelaria, M | 2 |
| Burgos, S | 1 |
| Ponce, M | 1 |
| Espinoza, R | 1 |
| Dueñas-Gonzalez, A | 2 |
| Lübbert, M | 2 |
| Kuendgen, A | 4 |
| Issa, JP | 3 |
| Garcia-Manero, G | 5 |
| Huang, X | 1 |
| Cortes, J | 3 |
| Ravandi, F | 3 |
| Jabbour, E | 3 |
| Borthakur, G | 1 |
| Brandt, M | 1 |
| Pierce, S | 2 |
| Kantarjian, HM | 5 |
| Ornstein, MC | 1 |
| Mukherjee, S | 1 |
| Jacob, L | 1 |
| Uvarova, M | 1 |
| Boulet, S | 1 |
| Begaj, I | 1 |
| Chevret, S | 2 |
| Yu, C | 1 |
| Chen, BA | 4 |
| Gao, C | 4 |
| Ding, JH | 3 |
| Xia, GH | 4 |
| Shao, ZY | 4 |
| Gao, F | 2 |
| Sun, YY | 2 |
| Cheng, J | 2 |
| Zhao, G | 3 |
| Wang, J | 3 |
| Song, HH | 2 |
| Ma, Y | 1 |
| Bao, W | 2 |
| Bellos, F | 1 |
| Mahlknecht, U | 1 |
| Nachtkamp, K | 1 |
| Kündgen, A | 1 |
| Strupp, C | 3 |
| Giagounidis, A | 1 |
| Kobbe, G | 1 |
| Gattermann, N | 3 |
| Haas, R | 3 |
| Voso, MT | 1 |
| Finelli, C | 2 |
| Musto, P | 1 |
| Pogliani, E | 1 |
| Angelucci, E | 1 |
| Fioritoni, G | 1 |
| Alimena, G | 1 |
| Maurillo, L | 1 |
| Cortelezzi, A | 1 |
| Buccisano, F | 1 |
| Gobbi, M | 1 |
| Borin, L | 1 |
| Di Tucci, A | 1 |
| Zini, G | 1 |
| Petti, MC | 1 |
| Martinelli, G | 2 |
| Fabiani, E | 1 |
| Fazi, P | 1 |
| Vignetti, M | 1 |
| Piciocchi, A | 1 |
| Liso, V | 1 |
| Amadori, S | 1 |
| Leone, G | 1 |
| Scott, BL | 1 |
| Liu, B | 1 |
| Ohishi, K | 1 |
| Yamamura, K | 1 |
| Suzuki, K | 1 |
| Monma, F | 1 |
| Ino, K | 1 |
| Nishii, K | 1 |
| Masuya, M | 1 |
| Sekine, T | 1 |
| Heike, Y | 1 |
| Takaue, Y | 1 |
| Katayama, N | 1 |
| Goodyear, O | 1 |
| Agathanggelou, A | 1 |
| Novitzky-Basso, I | 1 |
| Siddique, S | 1 |
| McSkeane, T | 1 |
| Ryan, G | 1 |
| Vyas, P | 1 |
| Cavenagh, J | 1 |
| Stankovic, T | 1 |
| Moss, P | 1 |
| Craddock, C | 1 |
| Herrera, A | 1 |
| Labardini, J | 1 |
| González-Fierro, A | 1 |
| Trejo-Becerril, C | 1 |
| Taja-Chayeb, L | 1 |
| Pérez-Cárdenas, E | 1 |
| de la Cruz-Hernández, E | 1 |
| Arias-Bofill, D | 1 |
| Vidal, S | 1 |
| Cervera, E | 1 |
| Follo, MY | 1 |
| Mongiorgi, S | 1 |
| Clissa, C | 1 |
| Chiarini, F | 1 |
| Ramazzotti, G | 1 |
| Paolini, S | 1 |
| Martelli, AM | 1 |
| Cocco, L | 1 |
| Zhang, B | 1 |
| Li, CR | 1 |
| Zhou, JF | 1 |
| Wu, XQ | 1 |
| Chen, J | 1 |
| Yang, H | 3 |
| Fang, Z | 1 |
| Wei, Y | 1 |
| Hu, Y | 1 |
| Calin, GA | 1 |
| Raffoux, E | 1 |
| Cras, A | 1 |
| Recher, C | 1 |
| Boëlle, PY | 1 |
| de Labarthe, A | 1 |
| Turlure, P | 1 |
| Marolleau, JP | 1 |
| Reman, O | 1 |
| Gardin, C | 1 |
| Victor, M | 1 |
| Maury, S | 1 |
| Rousselot, P | 1 |
| Malfuson, JV | 1 |
| Maarek, O | 1 |
| Daniel, MT | 1 |
| Degos, L | 1 |
| Chomienne, C | 1 |
| Dombret, H | 1 |
| Wang, AH | 1 |
| Wei, L | 1 |
| Chen, L | 1 |
| Zhao, SQ | 1 |
| Wu, WL | 1 |
| Shen, ZX | 1 |
| Li, JM | 1 |
| Zhang, QY | 1 |
| Ge, GM | 1 |
| Yan, YP | 1 |
| Han, XL | 1 |
| Huang, Y | 1 |
| Wu, S | 1 |
| He, LS | 1 |
| So, CC | 1 |
| Wong, KF | 1 |
| Aivado, M | 1 |
| Bernhardt, A | 1 |
| Hildebrandt, B | 2 |
| Pilatrino, C | 1 |
| Cilloni, D | 1 |
| Messa, E | 1 |
| Morotti, A | 1 |
| Giugliano, E | 1 |
| Pautasso, M | 1 |
| Familiari, U | 1 |
| Cappia, S | 1 |
| Pelicci, PG | 1 |
| Lo Coco, F | 1 |
| Saglio, G | 1 |
| Guerrasio, A | 1 |
| Knipp, S | 1 |
| Fox, F | 1 |
| Steidl, C | 1 |
| Yee, KW | 1 |
| Giles, FJ | 1 |
| Sanchez-Gonzalez, B | 1 |
| Rosner, G | 1 |
| Verstovsek, S | 1 |
| Rytting, M | 1 |
| Wierda, WG | 2 |
| Koller, C | 1 |
| Xiao, L | 1 |
| Faderl, S | 2 |
| Estrov, Z | 2 |
| O'brien, S | 1 |
| Estey, E | 1 |
| Bueso-Ramos, C | 1 |
| Fiorentino, J | 1 |
| Soriano, AO | 1 |
| Giles, F | 1 |
| Ouzounian, S | 1 |
| Quezada, A | 1 |
| Estey, EH | 1 |
| Siitonen, T | 1 |
| Timonen, T | 1 |
| Juvonen, E | 1 |
| Terävä, V | 1 |
| Kutila, A | 1 |
| Honkanen, T | 1 |
| Mikkola, M | 1 |
| Hallman, H | 1 |
| Kauppila, M | 1 |
| Nyländen, P | 1 |
| Poikonen, E | 1 |
| Rauhala, A | 1 |
| Sinisalo, M | 1 |
| Suominen, M | 1 |
| Savolainen, ER | 1 |
| Koistinen, P | 1 |
| Zhao, HH | 2 |
| Dohner, K | 2 |
| Dohner, H | 1 |
| Allan, RW | 1 |
| Shah, P | 1 |
| Mato, A | 1 |
| Luger, SM | 1 |
| Fawcett, RG | 1 |
| Chybicka, A | 1 |
| Kołecki, P | 1 |
| Pietras, W | 1 |
| Bogusławska-Jaworska, J | 1 |
| Wójcik, D | 1 |
| Armata, J | 1 |
| Eliasińska, A | 1 |
| Kowalczyk, J | 1 |
| Jackowska, T | 1 |
| Klus, K | 1 |
| Matysiak, M | 1 |
| Krauze, A | 1 |
| Stefańska, K | 1 |
| Rokicka-Milewska, R | 1 |
| Wiśniewska-Slusarz, H | 1 |
| Ganick, DJ | 1 |
| Sunder, T | 1 |
| Finley, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial[NCT04482621] | Phase 2 | 33 participants (Actual) | Interventional | 2020-09-14 | Active, not recruiting | ||
| Randomized Phase II Trial Seeking the Most Promising Drug Association With Azacitidine- in Higher Risk Myelodysplastic Syndromes[NCT01342692] | Phase 2 | 320 participants (Anticipated) | Interventional | 2011-06-30 | Active, not recruiting | ||
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Phase I/II Study of 5-aza-2'-Deoxycytidine and Valproic Acid in Patients With Relapsed/Refractory Leukemia or Myelodysplastic Syndromes[NCT00075010] | Phase 1/Phase 2 | 54 participants (Actual) | Interventional | 2004-01-23 | Completed | ||
| Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia[NCT00326170] | Phase 2 | 34 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy[NCT01617226] | Phase 2 | 260 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical activity of combination defined as: Complete Response (CR), bone marrow with 5% or fewer blasts and peripheral blood count with an absolute neutrophil count of 10^9/L or more and platelet count of 100x10^9 or more; Complete response without platelets (CRp), a complete response except for a platelet count less than 100x10^9 and transfusion independent; and Bone Marrow (BM) Response, bone marrow blast of 5% or less but without meeting the peripheral blood count criteria for (CR) or (CRp). (NCT00326170)
Timeframe: Up to 12 cycles of treatment (28 day cycles)
| Intervention | Participants (Number) | ||
|---|---|---|---|
| CR | CRp | BM | |
| VPA + 5-aza + ATRA | 12 | 3 | 7 |
6 reviews available for valproic acid and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Myelodysplas | 2023 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progre | 2015 |
Demethylating agents in myeloid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; D | 2008 |
Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Enzyme Inhibitors; Humans; Leukemia, Myeloid, | 2008 |
Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature.
Topics: Cytogenetic Analysis; Female; Histone Deacetylase Inhibitors; Humans; Middle Aged; Myelodysplastic S | 2007 |
Current status of epigenetic treatment in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinic | 2008 |
15 trials available for valproic acid and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Topics: Adult; Azacitidine; Bayes Theorem; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Myelodyspla | 2016 |
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Azacitidine; Cytochrome P-450 CYP2C19; DNA M | 2009 |
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Topics: Adult; Aged; Azacitidine; Cytogenetic Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DN | 2011 |
Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2011 |
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; | 2011 |
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Azacitidin | 2010 |
[The efficacy and safety of valproic acid in combination with low dose chemotherapy on intermediate and high-risk myelodysplastic syndrome].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Myel | 2011 |
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Male | 2004 |
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Topics: Acute Disease; Aged; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes | 2005 |
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell | 2005 |
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; Decit | 2006 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.
Topics: Acetylation; Aged; Aged, 80 and over; Calcitriol; Cheilitis; Chemical and Drug Induced Liver Injury; | 2007 |
[Treatment outcome for myelodysplastic syndromes (MDS) obtained by the Polish Children's Leukemia/Lymphoma Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool | 1998 |
20 other studies available for valproic acid and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Idarubicin; Lenalidomide; Myelodysplastic S | 2022 |
Valproic Acid Induced Thrombocytopenia and Dysmegakaryopoiesis in a Pediatric Patient.
Topics: Aged; Anticonvulsants; Bone Marrow; Child; Female; Humans; Myelodysplastic Syndromes; Thrombocytopen | 2022 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Tr | 2017 |
Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; D | 2015 |
[Sodium valproate synergizes adriamycin to inhibit proliferation and induce apoptosis in myelodysplastic syndrome cell line].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Myelodysplasti | 2008 |
Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Ger | 2009 |
Is survival enough for myelodysplastic syndromes?
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Ger | 2009 |
Clinical roundtable monograph. Combination therapies for MDS.
Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic | 2009 |
A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis.
Topics: Antigens, CD34; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; GABA Agents; GATA1 Transc | 2010 |
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Aged; Aged, 80 and over; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Comb | 2010 |
[Effect of sodium valproate on human myelodysplastic syndrome cell line SKM-1 and its mechanism].
Topics: Apoptosis; Calcium-Binding Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tu | 2010 |
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Ce | 2011 |
Valproate-associated dysmyelopoiesis in elderly patients.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Valproic Ac | 2002 |
Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; D | 2005 |
[Apoptosis of human myelodysplastic syndrome cell Line MUTZ-1 induced by sodium valproate].
Topics: Apoptosis; Cell Cycle; Cell Line; Dose-Response Relationship, Drug; Humans; Myelodysplastic Syndrome | 2007 |
[Effects of sodium valproate on proliferation and apoptosis of human myelodysplastic syndromes cell line MUTZ-1].
Topics: Apoptosis; Cell Cycle; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Re | 2007 |
Valproic acid for the treatment of myeloid malignancies.
Topics: Adult; Anticonvulsants; Female; Humans; Myelodysplastic Syndromes; Pilot Projects; Remission Inducti | 2008 |
Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder.
Topics: Anemia, Macrocytic; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Middle Aged; Myelod | 1997 |
Severe hematologic toxicity of valproic acid. A report of four patients.
Topics: Adolescent; Bone Marrow; Child, Preschool; Erythroid Precursor Cells; Female; Humans; Myelodysplasti | 1990 |